Advanced glycation end products and soluble receptor as markers of oxidative stress in children on hemodialysis

References

• Mahrooz A, Zargari M, Sedighi O, et al. Increased oxidized-LDL levels and arylesterase activity/HDL ratio in ESRD patients treated with hemodialysis. Clin Invest Med. 2012;35:E144–E151
   PubMed Web of Science ®Google Scholar
• Stenvinkel P. Inflammation in end-stage renal disease: The hidden enemy. Nephrology. 2006;11:36–41
   PubMed Web of Science ®Google Scholar
• Kalea AZ, Schmid TAM, Hudson BIAGE. A novel biological and genetic marker for vascular disease. Clin Sci (Lond). 2009;116:621–637
   PubMed Web of Science ®Google Scholar
• Zhang L, Postin AR, Wang Y. Ecto-domain shedding of the receptor for advanced glycation end products: A novel therapeutic target for Alzheimer’s disease. Cell Mol Life Sci. 2009;66:3923–3935
   PubMed Web of Science ®Google Scholar
• Vaziri ND. Oxidative stress in uremia: Nature, mechanisms, and potential consequences. Semin Nephrol. 2004;24(5):469–473
   PubMed Web of Science ®Google Scholar
• Thornalley PJ. Protein and nucleotide damage by glyoxal and methylglyoxal in physiological systems – Role in ageing and disease. Drug Metab Drug Interact. 2008;23(1–2):125–150
   PubMedGoogle Scholar
• Saito A, Takeda T, Sato K, et al. Significance of proximal tubular metabolism of advanced glycation end products in kidney diseases. Ann NY Acad Sci. 2005;1043:637–643
   PubMed Web of Science ®Google Scholar
• Stein G, Busch M, Muller A, et al. Are advanced glycation end products cardiovascular risk factors in patients with CRF? Am J Kidney Dis. 2003;41(3 Suppl. 1):S52–S56
   PubMed Web of Science ®Google Scholar
• Stenvinkel P, Carrero JJ, Axelsson J, Lind-Holm B, Heimburger O, Massy Z. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: How do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol. 2008;3(2):505–521
   PubMed Web of Science ®Google Scholar
• Thoms MC, Forbes JM, Maclsauc R, Jerums G, Cooper ME Low-molecular weight advanced glycation end products: Markers of tissue AGE accumulation and more. Ann NY Acad Sci. 2005;1043:644–654
   PubMed Web of Science ®Google Scholar
• Thomas MC, Forbes JM, Macisaac R, Jerums G, Cooper ME. Low-molecular weight advanced glycation end products: Markers of tissue AGE accumulation and more? Ann NY Acad Sci. 2005;1043:644–654
   PubMed Web of Science ®Google Scholar
• Thomas M, Tsalamandris C, MacIsaac R, et al. Low-molecular-weight AGEs are associated with GFR and anemia in patients with type 2 diabetes. Kidney Int. 2004;66:1167–1172
   PubMed Web of Science ®Google Scholar
• Schwedler SB, Metzger T, Schinzel R, Wanner C. Advanced glycation end products and mortality in hemodialysis patients. Kidney Int. 2002;62:301–310
   PubMed Web of Science ®Google Scholar
• Suliman ME, Heimburger O, Barany P, et al. Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. J Am Soc Nephrol. 2003;14:1614–1622
   PubMed Web of Science ®Google Scholar
• Busch M, Franke S, Muller A, et al. Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. Kidney Int. 2004;66:338–347
   PubMed Web of Science ®Google Scholar
• Giordano M, De Feo P, Lucidi P, et al. Increased albumin and fibrinogen synthesis in hemodialysis patients with normal nutritional status. J Am Soc Nephrol. 2001;12:349–354
   PubMed Web of Science ®Google Scholar
• Du Clos TW. Function of C-reactive protein. Ann Med. 2000;32:274–278
   PubMed Web of Science ®Google Scholar
• Kalousova M, Hodkova M, Kazderova M, et al. Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis. 2006;47:406–411
   PubMed Web of Science ®Google Scholar
• Farouk H, Kandil D, Kamel S, et al. Effect of GSTM1 and GSTT1 deletions in the development of oxidative stress in children with chronic kidney disease. J Clin Basic Cardiol. 2013;2013:16
   Google Scholar
• Robert MA, Thoms MC, Fernado D, Macmellan N, Power DA, Ierino FL. Low molecular weight advanced glycation end product predict morality in asymptomatic patients receiving chronic hemodialysis. Nephrol Dial Transplant. 2006;21:1611–1617
   PubMed Web of Science ®Google Scholar
• Cachofeiro V, Goicochea M, García de Vinuesa S, et al. Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int. 2008;74(Suppl. 111):S4–S9
   Web of Science ®Google Scholar
• Yamagishi S, Adachi H, Nakamura K, et al. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism. 2006;55:1227–1231
   PubMed Web of Science ®Google Scholar
• Kalousova M, Hodkova AM, Kazderova AM, et al. Soluble receptor for advanced glycation end products (sRAGE) in patients with decreased renal function. Am J Kidney Dis. 2006;47:406–411
   PubMed Web of Science ®Google Scholar
• Basta G, Lenoardis D, Mallamaci Allamaci F, et al. Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease. Kidney Int. 2010;77(3):225–231
   PubMed Web of Science ®Google Scholar
• Franke S, Muller A, Sommer M, Busch M, Kientsh-Engel R, Stein G. Serum levels of total homocysteine, homocysteine metabolites and of advanced glycation end-products (AGEs) in patients after renal transplantation. Clin Nephrol. 2003;59(2):88–97
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Kato I, Doi T, et al. Development and prevention of advanced diabetic nephropathy in RAGE-over expressing mice. J Clin Invest Clin Invest. 2001;108(2):261–268
   PubMed Web of Science ®Google Scholar
• Schmid A, Yan S, Brett J, Mora R, Nogrod R, Stern D. Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J Clin Invest. 1993;91:2155–2168
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington P, et al. Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: An analysis from the CARDS trial. Diabetes. 2011;60(9):2379–2385
   PubMed Web of Science ®Google Scholar
• Roberts MA, Fernando D, Macmillan N, et al. Single and serial measurements of cardiac troponin I in asymptomatic patients on chronic hemodialysis. Clin Nephrol. 2004;61:40–46
   PubMed Web of Science ®Google Scholar
• Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999;55:648–658
   PubMed Web of Science ®Google Scholar
• Koschinsky T, He CJ, Mitsuhashi T, et al. Orally absorbed reactive advanced glycation end products (glycotoxins): An environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA. 1997;94:6474–6479
   PubMed Web of Science ®Google Scholar
• He C, Sabol J, Mitsuhashi T, Vlassara H. Dietary glycotoxins: Inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration. Diabetes. 1999;48:1308–1315
   PubMed Web of Science ®Google Scholar
• Makita Z, Bucala R, Rayfield EJ, et al. Reactive glycosylation end products in diabetic uremia and treatment of renal failure. Lancet. 1994;343:1519–1522
   PubMed Web of Science ®Google Scholar
• Valencia JV, Mone M, Zhang J, et al. Divergent pathways of gene expression are activated by the RAGE ligands S100b and AGE-BSA. Diabetes. 2004;53:743–751
   PubMed Web of Science ®Google Scholar
• Falcone C, Emanuele E, D'angel OA, et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in non-diabetic men. Arterioscler Thromb Vasc Biol. 2005;25:1032–1037
   PubMed Web of Science ®Google Scholar
• Thomas MC, Baynes JW, Thorpe SR, Cooper ME. The Role of AGEs and AGE inhibitors in diabetic cardiovascular disease. Curr Drug Targets. 2005;6:453–474
   PubMed Web of Science ®Google Scholar
• Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med. 1984;101:527–537
   PubMed Web of Science ®Google Scholar
• Bucala R, Makita Z, Vega G, et al. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA. 1994;91:9441–9445
   PubMed Web of Science ®Google Scholar
• Uribarri J, Cai W, Peppa M, et al. Circulating glycotoxins and dietary advanced glycation endproducts: Two links to inflammatory response, oxidative stress, and aging. Biol Sci Med Sci. 2007;62(4):427–433
   Web of Science ®Google Scholar
• Uribarril J, Peppa M, Cai W, et al. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol. 2003;14:728–731
   PubMed Web of Science ®Google Scholar
• Tessitore N, Lapolla A, Arico NC, et al. Effect of protein leaking BK-F PMMA-based hemodialysis on plasma pentosidine levels. J Nephrol. 2004;17:707–714
   PubMed Web of Science ®Google Scholar
• Forbes JM, Thorpe SR, Thallas-Bonke V, et al. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol. 2005;16:2363–2372
   PubMed Web of Science ®Google Scholar
• Forbes JM, Thomas MC, Thorpe SR, Alderson NL, Cooper ME. The effects of valsartan on the accumulation of circulating and renal advanced glycation end products in experimental diabetes. Kidney Int. 2004;66:S105–S107
   Web of Science ®Google Scholar
• Macdougall IC, Cooper AC. Hyporesponsiveness to erythropoietic therapy due to chronic inflammation. Eur J Clin Invest. 2005;35(Suppl. 3):32–35
   PubMed Web of Science ®Google Scholar
• Thomas MC, Macisaac RJ, Tsalamandris C, et al. Unrecognized anemia inpatients with diabetes: A cross-sectional survey. Diabetes Care. 2003;26:1164–1169
   PubMed Web of Science ®Google Scholar